Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Smiths Detection enters healthcare field with diagnostic system

This article was originally published in Clinica

Executive Summary

Smiths Medical’s detection and screening unit has taken its first steps to break into the healthcare market by developing a rapid diagnostic system for infectious diseases. Smiths Detection, said to be a global leader in developing threat detection and screening technologies for military, transportation, homeland security and resilience applications, believes the clinical diagnostic version of its Bio-Seeq system will provide easy-to-use lab or point-of-care tests for diseases such as MRSA and Clostridium difficile. London, UK-based firm Smiths said that the test would not require manual sample preparation and a variety of solid and liquid samples can be used. The firm expects trials of clinical diagnostic system to begin in early 2009 and is currently seeking partners to co-develop a range of tests to run on the system. The underlying technology for Bio-Seeq is also being applied in animal health.

You may also be interested in...



Alere aided by professional diagnostics sales in fourth quarter

Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.

Integra and Stout to work on expandable interbody device

Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.

Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials

Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT040913

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel